“The price for the U.S. for the first 100 million doses was $19.50 per dose,” said BioNTech’s Chief Strategy Officer Ryan Richardson in an analyst call after the release of third quarter results on Tuesday. He was referring to a July deal struck by partner Pfizer with the U.S. government for the supply of the vaccine.
